Clinical Trial Update: Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab in MMR-proficient metastatic colorectal cancer using a pharmacologic priming approach to induce hypermutation has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: IFOM ETS - The AIRC Institute of Molecular Oncology | Conditions: Colorectal Neoplasms, Microsatellite Instability | Phase 2 | Status: COMPLETED | Results posted: 2026-03-03